i switched from semaglutide to tirzepatide Maintenance therapy on or Switching from Semaglutide to Tirzepatide:

Melnyk A, Albitar M, Bartram C, Oliff A, Andreeff M

122 EBDs also modulate histone accessibility through acetylation and methylation, promoting collagen synthesis and cell proliferation

A higher M1/M2 macrophage ratio in adipose tissue and the liver is associated with increased inflammatory responses, worsening insulin resistance and MASLD severity (208)

[1] [2] This raises the risk of calcium oxalate kidney stones and, in rare cases, oxalate nephropathy a condition where oxalate crystals deposit in kidney tissue, potentially causing lasting damage

Ocrevus (ocrelizumab) Disease area(s): Neurology/immunology Manufacturer(s): Roche 2024 Sales (USD): $7.66 billion Why it sold so well: In 2024, Roches multiple sclerosis (MS) therapy Ocrevus achieved sales of CHF 6.74 billion ($7.66 billion), marking a 9% increase from the previous year

Symptoms are often most noticeable when starting treatment or after a dose increase